Research and Markets: Systems Biology - Key to Unlocking the Value within the Omics Revolution.Business Editors/Health/Medical Writers DUBLIN, Ireland--(BUSINESS WIRE)--May 13, 2004 Market Projections for Systems Biology Systems biology, a field of study in the biosciences, focuses on the systematic study of complex interactions in biological systems. Particularly from 2000 onwards, the term is used widely in the biosciences, and in a variety of contexts. Products and Services Are Expected to Grow at an Annual Compound Rate of 66% to $785 Million By 2008 Research and Markets (http://www.researchandmarkets.com) has announced the addition of Systems Biology - Key to Unlocking the Value within the Omics Revolution to their offering. Systems biology, with its interdisciplinary approach to devising computational models
Agriculture operated by business; specifically, that part of a modern national economy devoted to the production, processing, and distribution of food and fibre products and byproducts. industries within systems biology. The recent availability of masses of omic (genomic, proteomic, and metabolomic) data is responsible for the major growth spurt growth spurt Pediatrics A period of rapid growth in middle adolescence; ♀ ↑ ±8 cm/yr ±age 12; ♂ ↑ ±10 cm/yr ± age 14; GS is orderly, affecting acral parts–ie, hands and feet grow before proximal regions, of systems biology. Pharmaceutical companies and others need to make sense out of all this omic information in order to take the next step in overcoming their innovation deficits. Systems biology provides the methods, computational capabilities, and inter-disciplinary expertise to facilitate this jump. Commercial applications are emerging at an accelerating pace as pharmaceutical and biotechnology research organizations start to combine various forms of omic data into more comprehensive computer models, and bioinformatics companies The primary purpose of this list is to serve as a holding place for the identities of Bioinformatics companies, particularly those for which articles have not yet been created. Three elements would be useful to include: a link to the article, a link to the company on the web (their increasingly turn their attention toward offering systems biology solutions to drug developers and diagnostics companies. This Report describes the current state and future prospects of the rapidly developing systems biology field. Our Systems Biology Report clearly defines what systems biology is and does. It includes: - An historical overview of the field is provided and the technical and commercial background. - An examination of the nature of systems biology in its several manifestations - commercial applications in pharmaceutical, diagnostic, and other business segments; and market dynamics. - A series of detailed profiles of companies active in the field - In-depth interviews with six systems biology experts. Market Opportunities -Create new paradigms New Paradigm In the investing world, a totally new way of doing things that has a huge effect on business. Notes: The word "paradigm" is defined as a pattern or model, and it has been used in science to refer to a theoretical framework. for improved drug target selection based on highly sophisticated predictive computational models of biological systems. -Expand the quality and sophistication so·phis·ti·cate v. so·phis·ti·cat·ed, so·phis·ti·cat·ing, so·phis·ti·cates v.tr. 1. To cause to become less natural, especially to make less naive and more worldly. 2. of new biomarkers to enhance the probability that a drug with a good preclinical preclinical /pre·clin·i·cal/ (-klin´i-k'l) before a disease becomes clinically recognizable. pre·clin·i·cal adj. 1. performance will succeed in human clinical trials and to reduce the costs of drug discovery and development by providing surrogates for subjective endpoints. -Increase the cost-benefit of diagnostic and therapeutic modalities therapeutic modality, n an intervention used to heal someone. See model, biomedical and homeopathy. via the reclassification Reclassification The process of changing the class of mutual funds once certain requirements have been met. These requirements are generally placed on load mutual funds. Reclassification is not considered to be a taxable event. of diseases in molecular rather than symptomatic or organ-specific terms. -Gain market leverage through the discovery of new diagnostic markers with vastly enhanced sensitivity and specificity. Key Reasons to Buy -Identify commercial opportunities in systems biology within the pharmaceutical, biotech and diagnostics markets via an in-depth assessment of the anticipated revenue distribution among target/biomarker licensing, software sales and services, solution providers, and computer vendors. -Discover the future possibilities of systems biology and the potential business models for systems biology companies from highly informative interviews with six industry veterans. -Recognize the full impact of systems biology from an overview of radically new products and services capable of making sense of genome-wide data and bridging the gap between information and knowledge. -Pinpoint the full market potential for systems biology products and services with an examination of the projected growth through 2008. -Look inside 18 companies active in systems biology, including their product pipelines, financial standing, technology research & development, alliances, and more. Report Contents: 1 Executive Summary 2 Introduction 3 Technology Background 4 Technologies for Systems Biology 5 Commercial Applicability 6 Market Activity and Prospects 7 Future Trends 8 Company Profiles Aclara Biosciences Beyond Genomics BioSeek, Inc Cellzome AG Entelos, Inc. Genedata AG GeneGo, Inc. Gene Network Sciences Gene Networks, Inc. Genomatica, Inc. IBM (International Business Machines Corporation, Armonk, NY, www.ibm.com) The world's largest computer company. IBM's product lines include the S/390 mainframes (zSeries), AS/400 midrange business systems (iSeries), RS/6000 workstations and servers (pSeries), Intel-based servers (xSeries) Corporation Strategic AlliancesIngenuity Systems The Institute for Systems Biology The Institute for Systems Biology (ISB) is a non-profit research institution, located in Seattle, Washington, United States. Leroy Hood co-founded the Institute with Alan Aderem and Ruedi Aebersold in 2000. Paradigm Genetics Predix Pharmaceuticals, Inc. Protein Pathways, Inc. Target Discovery 9 Interviews with Industry Experts For more information visit http://www.researchandmarkets.com/reports/c1966 |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion